These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 24751397)

  • 1. Increased hepatic CD36 expression with age is associated with enhanced susceptibility to nonalcoholic fatty liver disease.
    Sheedfar F; Sung MM; Aparicio-Vergara M; Kloosterhuis NJ; Miquilena-Colina ME; Vargas-Castrillón J; Febbraio M; Jacobs RL; de Bruin A; Vinciguerra M; García-Monzón C; Hofker MH; Dyck JR; Koonen DP
    Aging (Albany NY); 2014 Apr; 6(4):281-95. PubMed ID: 24751397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GPR40 deficiency is associated with hepatic FAT/CD36 upregulation, steatosis, inflammation, and cell injury in C57BL/6 mice.
    Lu Z; Li Y; Syn WK; Li AJ; Ritter WS; Wank SA; Lopes-Virella MF; Huang Y
    Am J Physiol Endocrinol Metab; 2021 Jan; 320(1):E30-E42. PubMed ID: 33103454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C.
    Miquilena-Colina ME; Lima-Cabello E; Sánchez-Campos S; García-Mediavilla MV; Fernández-Bermejo M; Lozano-Rodríguez T; Vargas-Castrillón J; Buqué X; Ochoa B; Aspichueta P; González-Gallego J; García-Monzón C
    Gut; 2011 Oct; 60(10):1394-402. PubMed ID: 21270117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombospondin 1 improves hepatic steatosis in diet-induced insulin-resistant mice and is associated with hepatic fat content in humans.
    Bai J; Xia M; Xue Y; Ma F; Cui A; Sun Y; Han Y; Xu X; Zhang F; Hu Z; Liu Z; Liu Y; Cai G; Su W; Sun X; Wu H; Yan H; Chang X; Hu X; Bian H; Xia P; Gao J; Li Y; Gao X
    EBioMedicine; 2020 Jul; 57():102849. PubMed ID: 32580141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. O-GlcNAcylation promotes the progression of nonalcoholic fatty liver disease by upregulating the expression and function of CD36.
    Zhu H; Zhao T; Zhao S; Yang S; Jiang K; Li S; Kang Y; Yang Z; Shen J; Shen S; Tao H; Xuan J; Yang M; Xu B; Wang F; Jiang M
    Metabolism; 2024 Jul; 156():155914. PubMed ID: 38642829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adipogenic changes of hepatocytes in a high-fat diet-induced fatty liver mice model and non-alcoholic fatty liver disease patients.
    Pan X; Wang P; Luo J; Wang Z; Song Y; Ye J; Hou X
    Endocrine; 2015 Apr; 48(3):834-47. PubMed ID: 25138963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of PDE4D in mouse liver is sufficient to trigger NAFLD and hypertension in a CD36-TGF-β1 pathway: therapeutic role of roflumilast.
    Tao X; He H; Peng J; Xu R; Fu J; Hu Y; Li L; Yang X; Feng X; Zhang C; Zhang L; Yu X; Shen A; Huang K; Fu Q
    Pharmacol Res; 2022 Jan; 175():106004. PubMed ID: 34826603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatocyte-Specific Disruption of CD36 Attenuates Fatty Liver and Improves Insulin Sensitivity in HFD-Fed Mice.
    Wilson CG; Tran JL; Erion DM; Vera NB; Febbraio M; Weiss EJ
    Endocrinology; 2016 Feb; 157(2):570-85. PubMed ID: 26650570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PEGylated Curcumin Derivative Attenuates Hepatic Steatosis via CREB/PPAR-
    Liu Y; Cheng F; Luo Y; Zhan Z; Hu P; Ren H; Tang H; Peng M
    Biomed Res Int; 2017; 2017():8234507. PubMed ID: 28770225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD36 promotes de novo lipogenesis in hepatocytes through INSIG2-dependent SREBP1 processing.
    Zeng H; Qin H; Liao M; Zheng E; Luo X; Xiao A; Li Y; Chen L; Wei L; Zhao L; Ruan XZ; Yang P; Chen Y
    Mol Metab; 2022 Mar; 57():101428. PubMed ID: 34974159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [KLF9 regulates hepatic lipid metabolism via inducing CD36 expression].
    Zhou SS; Zhang YL; Chang YS
    Sheng Li Xue Bao; 2021 Oct; 73(5):772-780. PubMed ID: 34708234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolactin improves hepatic steatosis via CD36 pathway.
    Zhang P; Ge Z; Wang H; Feng W; Sun X; Chu X; Jiang C; Wang Y; Zhu D; Bi Y
    J Hepatol; 2018 Jun; 68(6):1247-1255. PubMed ID: 29452209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis.
    Kim K; Ryu D; Dongiovanni P; Ozcan L; Nayak S; Ueberheide B; Valenti L; Auwerx J; Pajvani UB
    Gastroenterology; 2017 Dec; 153(6):1568-1580.e10. PubMed ID: 28859855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osteoprotegerin Promotes Liver Steatosis by Targeting the ERK-PPAR-γ-CD36 Pathway.
    Zhang C; Luo X; Chen J; Zhou B; Yang M; Liu R; Liu D; Gu HF; Zhu Z; Zheng H; Li L; Yang G
    Diabetes; 2019 Oct; 68(10):1902-1914. PubMed ID: 31292134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse Maternal Environment and Postweaning Western Diet Alter Hepatic CD36 Expression and Methylation Concurrently with Nonalcoholic Fatty Liver Disease in Mouse Offspring.
    Fu Q; North PE; Ke X; Huang YW; Fritz KA; Majnik AV; Lane RH
    J Nutr; 2021 Oct; 151(10):3102-3112. PubMed ID: 34486661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of receptor-interacting protein kinase 1 improves experimental non-alcoholic fatty liver disease.
    Majdi A; Aoudjehane L; Ratziu V; Islam T; Afonso MB; Conti F; Mestiri T; Lagouge M; Foufelle F; Ballenghien F; Ledent T; Moldes M; Cadoret A; Fouassier L; Delaunay JL; Aït-Slimane T; Courtois G; Fève B; Scatton O; Prip-Buus C; Rodrigues CMP; Housset C; Gautheron J
    J Hepatol; 2020 Apr; 72(4):627-635. PubMed ID: 31760070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low fat but not soy protein isolate was an effective intervention to reduce nonalcoholic fatty liver disease progression in C57BL/6J mice: monitored by a novel quantitative ultrasound (QUS) method.
    Rowles JL; Han A; Miller RJ; Kelly JR; Applegate CC; Wallig MA; O'Brien WD; Erdman JW
    Nutr Res; 2019 Mar; 63():95-105. PubMed ID: 30824402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of STING Is Increased in Liver Tissues From Patients With NAFLD and Promotes Macrophage-Mediated Hepatic Inflammation and Fibrosis in Mice.
    Luo X; Li H; Ma L; Zhou J; Guo X; Woo SL; Pei Y; Knight LR; Deveau M; Chen Y; Qian X; Xiao X; Li Q; Chen X; Huo Y; McDaniel K; Francis H; Glaser S; Meng F; Alpini G; Wu C
    Gastroenterology; 2018 Dec; 155(6):1971-1984.e4. PubMed ID: 30213555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TRUSS Exacerbates NAFLD Development by Promoting IκBα Degradation in Mice.
    Yu CJ; Wang QS; Wu MM; Song BL; Liang C; Lou J; Tang LL; Yu XD; Niu N; Yang X; Zhang BL; Qu Y; Liu Y; Dong ZC; Zhang ZR
    Hepatology; 2018 Nov; 68(5):1769-1785. PubMed ID: 29704259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B-cell lymphoma 6 alleviates nonalcoholic fatty liver disease in mice through suppression of fatty acid transporter CD36.
    Zhang H; Li Y; Zhang C; Huang K; Zhao J; Le S; Jiang L; Liu H; Yang P; Xiao X; Yu J; Wu J; Ye P; Xia J
    Cell Death Dis; 2022 Apr; 13(4):359. PubMed ID: 35436984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.